Aegle Therapeutics raised $2.73 million to advance AGLE-102, its stem cell–derived extracellular vesicle therapy for the treatment of dystrophic epidermolysis bullosa, a rare genetic disorder that causes severe skin blistering.
Investment Amount (In Millions): $2.73